TargED Eyes 2024 Clinic Entry For Clot Buster On Back Of Financing
€39m Raised In Series A
Executive Summary
The Dutch firm expects the financing to advance its novel asset Microlyse into a potentially pivotal study for a rare blood disorder.
You may also be interested in...
Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
Edgewise Touts Pan-Muscular Dystrophy Plans Following Early Promise In Becker
The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.
Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.